Chief Executive Officer and Managing Director, Amplia Therapeutics
| Role | Organisation | Sources |
|---|---|---|
| CEO (former) | Novonix | RenewEconomy (27 Sep 2023), RenewEconomy (20 Oct 2022) |
| Chief Executive Officer and Managing Director | Amplia Therapeutics | SMH Business, The Age Business |
Stories naming Dr Chris Burns. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Amplia has locked in the design of its PRROSE phase two study pairing narmafotinib with chemotherapy in ovarian cancer, to run with ANZGOG across Australia and New Zealand, recruiting about 26 patients.
Biotech Amplia Therapeutics has completed planning for its PRROSE phase two trial pairing narmafotinib with chemotherapy in ovarian cancer, working with ANZGOG, with patient recruitment targeted before the end of 2026.
Cytopia founder Andrew Wilks and Chris Burns won the 2024 Prime Minister's Prize for Innovation for inventing momelotinib, a rare blood-cancer drug the US FDA approved in 2023.
Novonix's Nova Scotia battery division has secured up to C$3 million in Canadian government R&D funding via NRC IRAP, supporting its dry cathode pilot line and a battery lifespan prediction project with SandboxAQ.
Novonix, an ASX-listed Brisbane battery materials firm, has been selected to negotiate a US$150 million US Department of Energy grant to expand synthetic graphite anode production, lifting its share price.